ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1028

Preexisting CKD Increases Risk of Metformin Monotherapy Failure in US Veterans with Type 2 Diabetes

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical


  • Gosmanova, Elvira O., Albany Stratton VA Medical Center, Albany, New York, United States
  • Gemoets, Darren E., Albany Stratton VA Medical Center, Albany, New York, United States
  • Kaminsky, Laurence S., Albany Stratton VA Medical Center, Albany, New York, United States
  • Kovesdy, Csaba P., Memphis VA Medical Center, Memphis, Tennessee, United States
  • Gosmanov, Aidar R., Albany Stratton VA Medical Center, Albany, New York, United States

Metformin (MET) is increasingly used for treatment of type 2 diabetes (T2D) in patients with chronic kidney disease stage 3 (CKD3); however, it is unknown if rates of MET monotherapy failure differs in patients with and without CKD3.


This was a retrospective study including 21,142 US Veterans with T2D and estimated glomerular filtration rate (eGFR) >30 ml/min/1.73m2 who initiated MET monotherapy between 01/2010 and 03/2017. CKD3 was established as eGFR 30-59 ml/min/1.73m2. MET monotherapy failure defined as the 1st 90-day gap in MET refill (MET discontinuation) or the addition of 2nd hypoglycemic agent (HA) during 3-yr follow up was compared between patients without and with CKD3 using univariate and multivariate Cox regression analyses adjusted for case-mix.


The mean ± SD age for the total cohort was 59.9 ±1 0.2 yrs, 94.3% were males, 79.7 and 17.3% were Whites and Blacks, respectively. Preexisting CKD3 was present in 1,363 (6.5%) patients. Baseline patients' characteristics were similar between two groups except CKD patients were older (68.7 vs. 59.3 yrs in non-CKD) and had lower eGFR (54.1 vs. 87.4ml/min1.73m2 in non-CKD). In Kaplan-Meyer analysis there were no difference in rates of MET discontinuation or addition of 2nd HA in patients without and with CKD3 (p=0.2 and p=0.09, respectively). However, in the adjusted analyses, patients with CKD3 had a significantly higher risk of MET discontinuation or addition of 2nd line HA (HR, 95% CI 1.15, 1.08-1.22 and 1.45; 1.30-1.61, respectively), as compared with no CKD (Figure 1).


In newly treated patients with T2D the presence of preexisting CKD stage 3 was associated with increased risk of MET monotherapy failure. MET discontinuation may be expected in CKD3 patients with the prorgession of CKD; however, our findings of the increased risk of addition 2nd HA warrant further studies to understand whether hypoglycemic efficacy of MET monotherapy is reduced in CKD stage 3.